STOCKHOLM, June 15, 2020 /PRNewswire/ -- IRRAS, a global
healthcare company with a comprehensive portfolio of innovative
products for neurocritical care, today announced the promotion
of Will Martin to President and
Chief Commercial Officer.
Today's announcement supports the company's ongoing acceleration
of its commercial launch. In this expanded role, Will Martin will continue to direct IRRAS'
global sales and marketing efforts and will also assume
responsibility for the various functions that directly support
commercial operations, including clinical affairs, regulatory, and
quality. In addition, he will also work closely with the IRRAS'
Chief Executive Officer, Kleanthis G.
Xanthopoulos, Ph.D., and Board of Directors to outline and
execute the company's long-term strategy.
"Since Will joined the IRRAS team, he has played a central role
in the expansion of our global commercial activity," said Dr.
Xanthopoulos. "His leadership has positively impacted the company's
progress over the past two years, and I am pleased to see him
assume these additional responsibilities."
"Moving forward, my singular focus remains the commercial
adoption of our product portfolio, and I am confident that my
expanded role will enhance the ability to achieve our revenue
goals," added Mr. Martin.
Mr. Martin joined IRRAS in early 2018 as Chief Commercial
Officer. Prior to joining IRRAS, he most recently served as General
Manager of the Peripheral Vascular (PV) devices business for
Philips Healthcare. Prior to this role, he held senior commercial
leadership positions at multiple early stage companies where he was
responsible for global product launches that produced profitable
returns for investors, including AccessClosure, Inc. (acquired by
Cardinal Health), Hotspur Technologies (acquired by Teleflex), and
AtheroMed, Inc. (acquired by Philips Volcano).
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker:
IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on June 15, 2020 at 08:30 (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-announces-promotion-of-will-martin-to-president-and-chief-commercial-officer,c3134108
View original
content:http://www.prnewswire.com/news-releases/irras-announces-promotion-of-will-martin-to-president-and-chief-commercial-officer-301076613.html
SOURCE IRRAS